Search Results - "Stricker, BHCh"

Refine Results
  1. 1

    Prevalence and determinants of undertreatment of hypertension in the Netherlands by SCHELLEMAN, H, KLUNGEL, O. H, KROMHOUT, D, DE BOER, A, STRICKER, Bhch, VERSCHUREN, W. M. M

    Published in Journal of human hypertension (01-05-2004)
    “…The objective of this study was to determine the prevalence, treatment, and control of hypertension, and the determinants of undertreatment in the Dutch…”
    Get full text
    Journal Article
  2. 2

    Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies by Stricker, B. H. Ch, Stijnen, T

    Published in European journal of epidemiology (01-04-2010)
    “…In pharmaco-epidemiology, the use of drugs is the determinant of interest when studying exposure-outcome associations. The increased availability of…”
    Get full text
    Journal Article
  3. 3

    The concordance between self‐reported medication use and pharmacy records in pregnant women by Cheung, K., El Marroun, H., Elfrink, M.E., Jaddoe, V.W.V., Visser, L.E., Stricker, B.H.Ch

    Published in Pharmacoepidemiology and drug safety (01-09-2017)
    “…Purpose Several studies have been conducted to assess determinants affecting the performance or accuracy of self‐reports. These studies are often not focused…”
    Get full text
    Journal Article
  4. 4

    Genetic Variation in the CYP2D6 Gene Is Associated With a Lower Heart Rate and Blood Pressure in β‐Blocker Users by Bijl, MJ, Visser, LE, Schaik, RHN, Kors, JA, Witteman, JCM, Hofman, A, Vulto, AG, Gelder, T, Stricker, BHCh

    Published in Clinical pharmacology and therapeutics (01-01-2009)
    “…Several β‐blockers are metabolized by the polymorphic enzyme cytochrome P450 2D6 (CYP2D6). CYP2D6*4 is the main polymorphism leading to decreased enzyme…”
    Get full text
    Journal Article
  5. 5

    Cytochrome P450 2C9 2 and 3 Polymorphisms and the Dose and Effect of Sulfonylurea in Type II Diabetes Mellitus by Becker, ML, Visser, LE, Trienekens, PH, Hofman, A, Schaik, RHN, Stricker, BHCh

    Published in Clinical pharmacology and therapeutics (01-02-2008)
    “…Sulfonylurea hypoglycemics are mainly metabolized by the cytochrome P450 2C9 (CYP2C9) enzyme. The CYP2C9*2 and *3 polymorphisms encode proteins with less…”
    Get full text
    Journal Article
  6. 6

    The healthy user and healthy adherer bias: a nested case-control study among statin users in the Rotterdam Study by Hollestein, Loes, Baser, Ömer, Stricker, BHCh, Nijsten, T

    “…Arch Public Health 73, O6 (2015). https://doi.org/10.1186/2049-3258-73-S1-O6 Download citation * Published: 17 September 2015 * DOI:…”
    Get full text
    Journal Article
  7. 7

    Antihypertensive drugs and incidence of dementia : the Rotterdam Study by IN'T VELD, B. A, RUITENBERG, A, HOFMAN, A, STRICKER, B. H. Ch, BRETELER, M. M. B

    Published in Neurobiology of aging (01-05-2001)
    “…There is increasing evidence that hypertension may contribute to the development of dementia. We investigated the relation of antihypertensive drug use and the…”
    Get full text
    Journal Article
  8. 8

    Genotypes Associated With Reduced Activity of VKORC1 and CYP2C9 and Their Modification of Acenocoumarol Anticoagulation During the Initial Treatment Period by Teichert, M, Schaik, RHN, Hofman, A, Uitterlinden, AG, Smet, PAGM, Stricker, BHCh, Visser, LE

    Published in Clinical pharmacology and therapeutics (01-04-2009)
    “…The objective of this study was to investigate the influence of genotypes associated with reduced activity of vitamin K epoxide reductase complex subunit 1…”
    Get full text
    Journal Article
  9. 9

    HMG‐CoA Reductase Inhibitors and the Risk of Vertebral Fracture by Schoofs, Mariette WCJ, Sturkenboom, Miriam CJM, van der Klift, Marjolein, Hofman, Albert, Pols, Huibert AP, Stricker, Bruno HCh

    Published in Journal of bone and mineral research (01-09-2004)
    “…Statins inhibit an enzyme in the mevalonate pathway and therefore may affect bone. In this first study on both symptomatic and nonsymptomatic vertebral…”
    Get full text
    Journal Article
  10. 10

    Evaluation of serological trials submitted for annual re-licensure of influenza vaccines to regulatory authorities between 1992 and 2002 by Voordouw, A.C.G, Beyer, W.E.P, Smith, D.J, Sturkenboom, M.C.J.M, Stricker, B.H.Ch

    Published in Vaccine (11-12-2009)
    “…Abstract Background As part of the regulatory requirements, serological evaluation of trivalent inactivated influenza vaccines must be performed before annual…”
    Get full text
    Journal Article
  11. 11

    ACE inhibitor-induced angioedema : Incidence, prevention and management by VLEEMING, W, VAN AMSTERDAM, J. G. C, STRICKER, B. H. C, DE WILDT, D. J

    Published in Drug safety (01-03-1998)
    “…Available information from 1980 to 1997 on angiotensin converting enzyme (ACE) inhibitor-induced angioedema and its underlying mechanisms are summarised and…”
    Get full text
    Journal Article
  12. 12

    Incidence, treatment, and case-fatality of non-traumatic subarachnoid haemorrhage in the Netherlands by Risselada, R, de Vries, L.M, Dippel, D.W.J, van Kooten, F, van der Lugt, A, Niessen, W.J, Firouzian, A, Stricker, B.H.Ch, Sturkenboom, M.C.J.M

    Published in Clinical neurology and neurosurgery (01-07-2011)
    “…Abstract Background Non-traumatic subarachnoid haemorrhage (SAH) is a devastating disorder and in the majority of cases it is caused by rupture of an…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Mefloquine increases the risk of serious psychiatric events during travel abroad: a nationwide case-control study in the Netherlands by van Riemsdijk, Melanie M, Sturkenboom, Miriam C J M, Pepplinkhuizen, Lolke, Stricker, Bruno H Ch

    Published in The journal of clinical psychiatry (01-02-2005)
    “…Psychiatric events during travel abroad account for a large percentage of medical repatriations arranged by insurance companies. Several risk factors have been…”
    Get full text
    Journal Article
  15. 15

    Genetic polymorphisms and heart failure by Bleumink, Gysèle S., Schut, Anna F.C., Sturkenboom, Miriam C.J.M., Deckers, Jaap W., van Duijn, Cornelia M., Stricker, Bruno H.Ch

    Published in Genetics in medicine (01-11-2004)
    “…Heart failure is a complex clinical syndrome. There is evidence for a genetic contribution to the pathophysiology of heart failure. Considering the fundamental…”
    Get full text
    Journal Article
  16. 16

    Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort by DIELEMAN, Jeanne P, JAMBROES, Marielle, BRINKMAN, Kees, GYSSENS, Inge C, STURKENBOOM, Miriam C. J. M, STRICKER, Bruno H. Ch, MULDER, Wilhelmina M. C, DE WOLF, Frank, WEVERLING, Gerrit-Jan, LANGE, Joep M. A, REISS, Peter

    Published in AIDS (London) (29-03-2002)
    “…Toxicity is the most important reason for premature switching of highly active antiretroviral therapy (HAART). In order to optimize the benefit-risk ratio of…”
    Get full text
    Journal Article
  17. 17

    NSAIDs and incident Alzheimer’s disease. the Rotterdam study by In ’t Veld, B.A, Launer, L.J, Hoes, A.W, Ott, A, Hofman, A, Breteler, M.M.B, Stricker, B.H.Ch

    Published in Neurobiology of aging (01-11-1998)
    “…Recent studies suggest that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce the risk for Alzheimer’s disease (AD). We investigated the…”
    Get full text
    Journal Article
  18. 18

    Determinants of DNA yield and purity collected with buccal cell samples by van Wieren-de Wijer, D. B. M. A, Maitland-van der Zee, A. H, de Boer, A, Belitser, S. V, Kroon, A. A, de Leeuw, P. W, Schiffers, P, Janssen, R. G. J. H, van Duijn, C. M, Stricker, B. H. C. H, Klungel, O. H

    Published in European journal of epidemiology (2009)
    “…Buccal cells are an important source of DNA in epidemiological studies, but little is known about factors that influence amount and purity of DNA. We assessed…”
    Get full text
    Journal Article
  19. 19

    Differential roles of Angiotensinogen and Angiotensin Receptor type 1 polymorphisms in breast cancer risk by GONZALEZ-ZULOETA LADD, A. M, ARIAS VASQUEZ, A, SIEMES, C, YAZDANPANAH, M, COEBERGH, J. W, HOFMAN, A, STRICKER, B. H. Ch, VAN DUIJN, C. M

    Published in Breast cancer research and treatment (01-03-2007)
    “…While angiotensinogen (AGT) seems to have anti proliferative properties, angiotensin II (ATII) is a potent growth factor and it mediates its actions through…”
    Get full text
    Journal Article
  20. 20

    Pharmacogenetic interactions of three candidate gene polymorphisms with ACE‐inhibitors or β‐blockers and the risk of atherosclerosis by Schelleman, H., Klungel, O. H., Witteman, J. C. M., Hofman, A., Van Duijn, C. M., De Boer, A., Stricker, B. H. CH

    Published in British journal of clinical pharmacology (01-07-2007)
    “…What is already known about this subject • To our knowledge, there are no prior studies which investigate whether there is a drug–gene interaction between the…”
    Get full text
    Journal Article